Chemed Stock Rises After Strong Q1 2026 Earnings Beat, Revenue Growth and Higher Full-Year Guidance

Chemed Corporation gained investor attention after reporting first-quarter 2026 results that came in ahead of earnings expectations, supported by steady revenue growth, stronger VITAS performance, share repurchases, and improved full-year guidance. The company reported adjusted earnings of $5.65 per share and revenue of $657.5 million for the quarter ended March 31, 2026.

Q1 Earnings Beat Expectations

Chemed’s first-quarter performance showed that the company remains financially resilient even while facing mixed business conditions across its two major segments: VITAS Healthcare and Roto-Rooter. Adjusted diluted EPS rose slightly year over year to $5.65, while GAAP diluted EPS was $4.84. Revenue increased 1.6% from the prior-year period, reflecting continued demand in hospice services and stable activity in plumbing and drain-cleaning operations.

The stronger-than-expected earnings result helped support positive market sentiment around CHE stock. Investors appeared encouraged by the earnings beat, the improved outlook, and management’s confidence in VITAS’ recovery and growth trajectory.

VITAS Healthcare Drives Growth

VITAS, Chemed’s hospice-care business, was the main growth driver in the quarter. The segment generated $420.0 million in net patient revenue, up 3.1% year over year. Average daily census increased 2.2%, while admissions rose 6.9%, showing better patient volume and stronger demand for end-of-life care services.

Management said VITAS benefited from improved operating momentum after challenges connected to the 2025 Medicare Cap issue. The company now expects stronger 2026 growth from VITAS than originally projected. This improvement was important because hospice care remains Chemed’s largest revenue contributor and a major source of earnings stability.

VITAS Margins Still Face Pressure

Although VITAS revenue improved, profitability was not perfect. Adjusted EBITDA excluding Medicare Cap rose only 0.6% to $70.8 million, while adjusted EBITDA margin slipped to 16.8%. The margin decline shows that higher revenue did not fully translate into stronger operating leverage during the quarter. Still, the segment’s admissions growth and better census trends gave management enough confidence to lift guidance.

Roto-Rooter Results Were Softer

Roto-Rooter, Chemed’s plumbing and drain-cleaning business, reported revenue of $237.5 million, down 0.9% from the prior-year quarter. Adjusted EBITDA declined 9.6% to $53.5 million, and adjusted EBITDA margin fell by 218 basis points to 22.5%.

The segment faced pressure from weaker water restoration demand, higher marketing expenses, and weather-related disruptions. Chemed said unusual ice and snowstorms affected service activity across 24 Roto-Rooter branches for several days during the quarter. Even so, the company kept its full-year Roto-Rooter revenue growth expectation unchanged at 3.0% to 3.5%.

Franchise Acquisitions Support Long-Term Strategy

During the quarter, Roto-Rooter acquired franchise territories in San Francisco, California and Fort Worth, Texas for about $20.6 million. These acquisitions are expected to add around $5.0 million to $5.5 million in revenue for the rest of 2026. This move supports Chemed’s strategy of expanding company-owned operations in attractive markets.

Chemed Raises 2026 Earnings Guidance

One of the biggest takeaways from the report was Chemed’s decision to raise its full-year 2026 adjusted EPS guidance. The company now expects adjusted earnings per diluted share between $24.00 and $24.75, compared with its prior range of $23.25 to $24.25.

This improved outlook reflects stronger VITAS performance, the impact of share buybacks, and management’s belief that hospice growth is returning faster than expected. The midpoint of the updated guidance represents meaningful growth compared with 2025 adjusted EPS of $21.55.

Share Repurchases Boost Investor Confidence

Chemed repurchased 500,000 shares during the quarter for approximately $197.7 million, at an average price of $395.36 per share. As of March 31, 2026, the company still had about $229.6 million remaining under its share repurchase authorization.

Share repurchases can support earnings per share by reducing the number of shares outstanding. For investors, this often signals that management believes the company’s stock offers value, especially when combined with stronger guidance.

Balance Sheet and Liquidity

At the end of the quarter, Chemed had $16.9 million in cash and cash equivalents and $91.2 million in long-term debt. The company also entered into a new five-year $450 million credit agreement in April 2026, giving it additional financial flexibility for operations, acquisitions, and shareholder returns.

Market Reaction to CHE Stock

CHE stock moved higher after the report as investors reacted positively to the earnings beat and raised outlook. While Roto-Rooter’s margin decline created some concern, the strength in VITAS and the company’s updated guidance helped balance the picture.

Overall, Chemed’s first-quarter report showed a company with two very different business stories. VITAS is improving faster than expected and helping lift the company’s outlook. Roto-Rooter remains profitable but is dealing with short-term pressure from marketing costs, weaker restoration activity, and weather disruptions.

What Investors Should Watch Next

Going forward, investors will likely focus on whether VITAS can keep growing admissions and average daily census while improving margins. They will also watch whether Roto-Rooter can recover from its soft first quarter and bring marketing costs under better control.

Chemed’s updated guidance suggests management sees more upside than downside in 2026. However, continued margin pressure, healthcare reimbursement changes, and weaker demand in certain home-service categories could still affect results.

Conclusion

Chemed delivered a solid first quarter, with adjusted earnings beating expectations and revenue growing modestly. VITAS Healthcare was the clear bright spot, while Roto-Rooter showed weaker profitability. The company’s higher full-year guidance, large share repurchase activity, and strategic franchise acquisitions helped strengthen investor confidence.

While margin pressure remains a key issue, Chemed’s latest results suggest the company is on a stronger path for 2026, especially if VITAS continues to outperform and Roto-Rooter stabilizes in the coming quarters.

#Chemed #CHEStock #Q1Earnings #StockMarketNews #SlimScan #GrowthStocks #CANSLIM